A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
暂无分享,去创建一个
[1] C. Pinsky,et al. The management of plasma cell neoplasms. , 1971, The Medical clinics of North America.
[2] D. Karnofsky,et al. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma , 1948 .
[3] A. Gornall,et al. Determination of serum proteins by means of the biuret reaction. , 1949, The Journal of biological chemistry.
[4] Jack E. Meyer,et al. „solitary”︁ myeloma of bone a review of 12 cases , 1974, Cancer.
[5] H. Fudenberg,et al. "Sandwich" solid phase radioimmunoassay for the quantitative deterimination of human immunoglobulins. , 1969, Journal of immunology.
[6] H. Preuss,et al. The effect of Bence Jones protein on the in vitro function of rabbit renal cortex. , 1968, Nephron.
[7] S. Salmon,et al. Cellular kinetics in multiple myeloma. A new approach to staging and treatment. , 1975, Archives of internal medicine.
[8] T. Waldmann,et al. METABOLISM OF BENCE JONES PROTEINS. , 1964, The Journal of clinical investigation.
[9] G. Moore,et al. Production of Free Light Chains of Immunoglobulin by a Hematopoietic Cell Line Derived from a Patient with Multiple Myeloma.∗ , 1967, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[10] T. Waldmann,et al. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. , 1972, The Journal of clinical investigation.
[11] J. Fahey,et al. THE FORMATION OF MYELOMA PROTEIN BY A MOUSE PLASMA CELL TUMOR , 1958, The Journal of experimental medicine.
[12] W Strober,et al. Metabolism of immunoglobulins. , 1969, Progress in allergy.
[13] Bergsagel De. Plasma cell myeloma. An interpretive review. , 1972 .
[14] H. H. Lloyd,et al. Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. , 1970, Cancer chemotherapy reports.
[15] E. Gehan. A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. , 1965, Biometrika.
[16] H. Skipper. Thoughts on cancer chemotherapy and combination modality therapy (1974). , 1974, JAMA.
[17] D. Bergsagel,et al. The treatment of plasma cell myeloma. , 1967, Advances in cancer research.
[18] F. Schabel,et al. The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors. , 1969, Cancer research.
[19] E. Gehan,et al. Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. , 1967, The American journal of medicine.
[20] A. Goldin. Factors pertaining to complete drug-induced remission of tumor in animals and man. , 1969, Cancer research.
[21] R. Peto. Urea, albumin, and response rates. , 1971, British medical journal.
[22] W. Pruzanski,et al. Treatment of plasma cell myeloma with cytotoxic agents. , 1975, Archives of internal medicine.
[23] S. Salmon,et al. Sandwich solid phase radioimmunoassays for the characterization of human immunoglobulins synthesized in vitro. , 1970, Journal of immunology.
[24] E. Osserman,et al. The treatment of multiple myeloma. , 1973, Seminars in hematology.
[25] J. Hobbs. Growth Rates and Responses to Treatment in Human Myelomatosis , 1969, British journal of haematology.
[26] J. Blainey,et al. Urinary lysozyme, ribonuclease, and low-molecular-weight protein in renal disease. , 1968, Lancet.
[27] S. Salmon,et al. Kinetics of tumor growth and regression in IgG multiple myeloma. , 1972, The Journal of clinical investigation.
[28] S. Salmon,et al. Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. , 1970, The Journal of clinical investigation.
[29] D. Bergsagel,et al. Myeloma Proteins and the Clinical Response to Melphalan Therapy , 1965, Science.
[30] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[31] A. Dawson,et al. Factors influencing the prognosis in myelomatosis , 1971, Postgraduate medical journal.
[32] Eisenberg,et al. Interpretation of Serum Calcium in Patients with Abnormal Serum Proteins , 1973, British medical journal.
[33] R. Hiramoto,et al. Quantitation of total-body tumor cells (MOPC 104E). I. Subcutaneous tumor model. , 1974, Journal of the National Cancer Institute.
[34] E. Osserman,et al. Melphalan and Antigenic Type of Bence Jones Proteins in Myeloma , 1965, Science.
[35] T. Waldmann,et al. THE ROLE OF THE KIDNEY IN THE CATABOLISM OF BENCE JONES PROTEINS AND IMMUNOGLOBULIN FRAGMENTS , 1967, The Journal of experimental medicine.
[36] P. Carbone,et al. Melphalan and prednisone: An effective combination for the treatment of multiple myeloma , 1973 .
[37] O. P. Hansen,et al. Prognosis of myelomatosis on treatment with prednisone and cytostatics. , 2009, Scandinavian journal of haematology.
[38] S. Hellman. Current studies in Hodgkin's disease: what laparotomy has wrought. , 1974, The New England journal of medicine.